Tc 99m nofetumomab merpentan

Drug Profile

Tc 99m nofetumomab merpentan

Alternative Names: F(ab)2 NRLU10 technetium (Tc 99m); OncoTrac; OncoTrac NSCLC; OncoTrac SCLC; Technetium Tc 99m-nofetumomab merpentan; VerLuma

Latest Information Update: 21 Jun 2006

Price : $50

At a glance

  • Originator Poniard Pharmaceuticals
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 21 Jun 2006 NeoRx Corporation is now called Poniard Pharmaceuticals Inc.
  • 22 May 1997 Launched for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
  • 12 Feb 1997 Registered for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top